Zentalis Pharmaceuticals, Inc. (ZNTL)

NASDAQ: ZNTL · IEX Real-Time Price · USD

3.570

-0.620 (-14.80%)

At close: Jul 2, 2024, 4:00 PM

3.730

+0.160 (4.48%)

After-hours: Jul 2, 2024, 7:52 PM EDT

Zentalis Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	64.35	54.55	40.94	33.89	8.46	Upgrade
Research & Development	235.16	172.73	175.6	84.9	38.39	Upgrade
Operating Expenses	299.51	227.29	216.54	118.79	46.85	Upgrade
Operating Income	-299.51	-227.29	-216.54	-118.79	-46.85	Upgrade
Other Expense / Income	-6.72	9.99	-57.52	-1.39	-1.2	Upgrade
Pretax Income	-292.79	-237.28	-159.02	-117.4	-45.65	Upgrade
Income Tax	-0.6	-0.47	-0.3	0.44	0.02	Upgrade
Net Income	-292.19	-236.81	-158.73	-117.84	-45.66	Upgrade
Shares Outstanding (Basic)	65	53	43	28	6	Upgrade
Shares Outstanding (Diluted)	65	53	43	28	6	Upgrade
Shares Change	23.75%	23.82%	51.84%	402.29%	0.05%	Upgrade
EPS (Basic)	-4.47	-4.48	-3.72	-4.19	-	Upgrade
EPS (Diluted)	-4.47	-4.48	-3.72	-4.19	-	Upgrade
Free Cash Flow	-208.41	-166.3	-160.2	-87.58	-39.5	Upgrade
Free Cash Flow Per Share	-3.19	-3.15	-3.75	-3.12	-7.06	Upgrade
EBITDA	-291.4	-235.85	-158.48	-117.24	-45.54	Upgrade
Depreciation & Amortization	1.39	1.43	0.54	0.16	0.11	Upgrade
EBIT	-292.79	-237.28	-159.02	-117.4	-45.65	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).